Drugs / ANG003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06052293 | Aug 2023 → Jul 2024 | exocrine pancreatic insufficiency | Anagram Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07450547 | Apr 2026 → Jul 2027 expected | cystic fibrosis, exocrine pancreatic insufficiency | Anagram Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-27 | Anagram Therapeutics, Inc. | Results Anagram Therapeutics Presents Positive Data from Clinical Study in People with Cystic Fibrosis (CF) Related Exocrine Pancreatic Insufficiency at North American CF Conference anagramtx.com ↗
ANG003 was Well Tolerated and Demonstrated a Statistically Significant Dose-Dependent Increase in DHA and EPA Fat Absorption |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANG003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06052293 ↗ |
| Modality | Protein / enzyme biologic | “ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"),” NCT07450547 ↗ |
| Route | Oral | “orally administered ANG003” NCT06052293 ↗ |